Following a full submission
AWMSG advice |
||||
| Status: Recommended | ||||
Ziconotide (Prialt®) is recommended as an option for use in NHS Wales for the treatment of severe chronic pain in adults who require intrathecal analgesia. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
||||
|
||||
Medicine details |
||||
| Medicine name | ziconotide (Prialt®) | |||
| Formulation | 100 micrograms/ml solution for intrathecal infusion | |||
| Reference number | 5385 | |||
| Indication | Treatment of severe, chronic pain in adults who require intrathecal (IT) analgesia |
|||
| Company | Esteve Limited | |||
| BNF chapter | Central nervous system | |||
| Assessment type | Full | |||
| Status | Recommended | |||
| Advice number | 0125 | |||
| NMG meeting date | 20/03/2025 | |||
| AWMSG meeting date | 20/05/2025 | |||
| Date of issue | 29/05/2025 | |||
| Commercial arrangement | WPAS | |||
| Further information This advice replaces the previous AWMSG recommendation for ziconotide (Prialt®) (AWTTC reference number 335, originally published July 2008). |
||||